Literature DB >> 2116309

Alpha 1----3-galactosyltransferase: the use of recombinant enzyme for the synthesis of alpha-galactosylated glycoconjugates.

D H Joziasse1, N L Shaper, L S Salyer, D H Van den Eijnden, A C van der Spoel, J H Shaper.   

Abstract

We have reported the isolation and characterization of a bovine cDNA clone containing the complete coding sequence for UDP-Gal:Gal beta 1----4GlcNAc alpha 1----3-galactosyltransferase [Joziasse, D. H., Shaper, J. H., Van den Eijnden, D. H., Van Tunen, A. J. & Shaper, N. L. (1989) J. Biol. Chem. 264, 14290-14297]. Insertion of this cDNA clone into the genome of Autographa californica nuclear polyhedrosis virus (AcNPV) and subsequent infection of Spodoptera frugiperda (Sf9) insect cells with recombinant virus, resulted in high-level expression of enzymatically active alpha 1----3-galactosyltransferase. The expressed enzyme accounted for about 2% of the cellular protein; the corresponding specific enzyme activity was 1000-fold higher than observed in calf thymus, the tissue with the highest specific enzyme activity reported to date. The recombinant alpha 1----3-galactosyltransferase could be readily detergent-solubilized and subsequently purified by affinity chromatography on UDP-hexanolamine-Sepharose. The recombinant alpha 1----3-galactosyltransferase showed the expected preference for the acceptor substrate N-acetyllactosamine (Gal beta 1----4GlcNAc), and demonstrated enzyme kinetics identical to those previously reported for affinity-purified calf thymus alpha 1----3-galactosyltransferase [Blanken, W. M. & Van den Eijnden, D. H. (1985) J. Biol. Chem. 260, 12927-12934]. In pilot studies, the recombinant enzyme was examined for the ability to synthesize alpha 1----3-galactosylated oligosaccharides, glycolipids and glycoproteins. By a combination of 1H-NMR, methylation analysis, HPLC, and exoglycosidase digestion it was established that, for each of the model compounds, the product of galactose transfer had the anticipated terminal structure, Gal alpha 1----3Gal beta 1----4-R. Our results demonstrate that catalysis by recombinant alpha 1----3-galactosyltransferase can be used to obtain preparative quantities of various alpha 1----3-galactosylated glycoconjugates. Therefore, enzymatic synthesis using the recombinant enzyme is an effective alternative to the chemical synthesis of these biologically relevant compounds.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2116309     DOI: 10.1111/j.1432-1033.1990.tb19095.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  7 in total

1.  Expression of stable human O-glycan core 2 beta-1,6-N-acetylglucosaminyltransferase in Sf9 insect cells.

Authors:  D Toki; M Sarkar; B Yip; F Reck; D Joziasse; M Fukuda; H Schachter; I Brockhausen
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

2.  The living factory: in vivo production of N-acetyllactosamine containing carbohydrates in E. coli.

Authors:  E Bettler; E Samain; V Chazalet; C Bosso; A Heyraud; D H Joziasse; W W Wakarchuk; A Imberty; A R Geremia
Journal:  Glycoconj J       Date:  1999-03       Impact factor: 2.916

3.  Profiling terminal N-acetyllactosamines of glycans on mammalian cells by an immuno-enzymatic assay.

Authors:  Haruko Ogawa; Uri Galili
Journal:  Glycoconj J       Date:  2006-11-18       Impact factor: 2.916

4.  One-pot enzymatic synthesis of the Gal alpha 1-->3Gal beta 1-->4GlcNAc sequence with in situ UDP-Gal regeneration.

Authors:  C H Hokke; A Zervosen; L Elling; D H Joziasse; D H van den Eijnden
Journal:  Glycoconj J       Date:  1996-08       Impact factor: 2.916

5.  Vaccination-induced IgG response to Galalpha1-3GalNAc glycan epitopes in lambs protected against Haemonchus contortus challenge infection.

Authors:  Caroline M W van Stijn; Marloes van den Broek; Lonneke Vervelde; Richard A Alvarez; Richard D Cummings; Boris Tefsen; Irma van Die
Journal:  Int J Parasitol       Date:  2009-08-18       Impact factor: 3.981

6.  Expression of recombinant rabbit UDP-GlcNAc: alpha 3-D-mannoside beta-1,2-N-acetylglucosaminyltransferase I catalytic domain in Sf9 insect cells.

Authors:  M Sarkar
Journal:  Glycoconj J       Date:  1994-06       Impact factor: 2.916

Review 7.  Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present α-gal epitopes.

Authors:  Uri Galili
Journal:  Vaccine       Date:  2020-08-19       Impact factor: 3.641

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.